V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

10x Genomics Executive Compensation (FY25)

TXG · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 8, 2026
217 figures on this page: 212 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Companies named in the disclosed peer group include Azenta, Inc., Bio-Techne Corp., Certara, Inc., Exact Sciences Corporation and GoodRx Holdings, Inc., among others. Total compensation for Serge Saxonov, Chief Executive Officer, came to $6,329,244 in fiscal 2025, and Saxonov's total was 20.2% lower than the $7,929,349 reported for fiscal 2024. For fiscal 2025, the company reported a chief executive pay ratio of 32:1, against median employee compensation of $196,532. For fiscal 2025, shareholders backed the say-on-pay proposal with 98.4% of votes cast for or against in favor at the meeting held June 4, 2026.
Chief executive, fiscal 2025
◇
Serge Saxonov
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Serge Saxonov: $7,929,349 → $6,329,244 (20.2% lower)
Say-on-pay support: 83.6% → 98.4% (14.8 points higher)
CEO pay ratio: 39:1 → 32:1 (17.9% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is 10x Genomics' chief executive and what were they paid?
Total compensation for Serge Saxonov, Chief Executive Officer, came to $6,329,244 in fiscal 2025. Saxonov's total was 20.2% lower than the $7,929,349 reported for fiscal 2024.
What was 10x Genomics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.4% of votes cast for or against in favor at the meeting held June 4, 2026.
Which companies are in 10x Genomics' peer group?
Companies named in the disclosed peer group include Azenta, Inc., Bio-Techne Corp., Certara, Inc., Exact Sciences Corporation and GoodRx Holdings, Inc., among others.
What is 10x Genomics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 32:1, against median employee compensation of $196,532.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Serge Saxonov
Chief Executive Officer
◇—◇◇◇——◇
Benjamin Hindson
President and Chief Scientific Officer
◇—◇◇◇——◇
Eric Whitaker
Former Chief Legal Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Serge Saxonov
Chief Executive Officer
◇—◇—◇——◇
Eric Whitaker
Chief Legal Officer
◇—◇—◇——◇
Benjamin Hindson
President and Chief Scientific Officer
◇—◇—◇——◇
Adam Taich
Chief Financial Officer
◇—◇—◇——◇
Justin McAnear
Former Chief Financial Officer
Departed during or after this year
◇—◇————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Serge Saxonov
Chief Executive Officer
◇—◇—◇——◇
Eric Whitaker
Former Chief Legal Officer
Departed during or after this year
◇—◇—◇——◇
Benjamin Hindson
President and Chief Scientific Officer
◇—◇—◇——◇
Adam Taich
Chief Financial Officer
◇—◇—◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam S. TaichRSU◇——◇——◇
Benjamin J. HindsonPSU◇◇◇—◇—◇
Benjamin J. HindsonPSU◇◇◇—◇—◇
Benjamin J. HindsonRSU◇——◇——◇
Eric S. WhitakerPSU◇◇◇—◇—◇
Eric S. WhitakerRSU◇——◇——◇
Eric S. WhitakerPSU◇◇◇—◇—◇
Serge SaxonovRSU◇——◇——◇
Serge SaxonovPSU◇◇◇—◇—◇
Serge SaxonovPSU◇◇◇—◇—◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric WhitakerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/22/2032
Option◇—◇9/14/2032
Option◇—◇3/21/2033
Benjamin HindsonRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/22/2032
Option◇—◇9/14/2032
Option◇—◇3/21/2033
Serge SaxonovRSU◇◇——
Option◇—◇3/21/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/22/2032
Adam TaichRSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John R. Stuelpnagel
Board chair
◇◇————◇
Sri Kosaraju
◇◇———◇◇
Kimberly J. Popovits
◇◇———◇◇
Shehnaaz Suliman
◇◇———◇◇
Alan Mateo
◇◇————◇
Sarah Teichmann
◇◇———◇◇
Benjamin J. Hindson, Serge Saxonov and Mathai Mammen served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: Executives and directors are subject to stock ownership guidelines which align their interests with our stockholders.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Azenta, Inc. AZTA
  • Bio-Techne Corp. TECH
  • Certara, Inc. CERT
  • Exact Sciences Corporation EXAS
  • GoodRx Holdings, Inc. GDRX
  • Guardant Health, Inc. GH
  • Haemonetics Corporation HAE
  • Inari Medical, Inc. NARI
  • Insulet Corporation PODD
  • iRhythm Technologies, Inc. IRTC
  • Maravai Lifesciences Holdings, Inc. MRVI
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • NeoGenomics, Inc. NEO
  • NovoCure Limited NVCR
  • Penumbra, Inc. PEN
  • Repligen Corporation RGEN
  • Sotera Health Company SHC
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 3, 2025=◇◇◇
2023June 11, 2024=◇◇◇
2022June 14, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when 10x Genomics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact 10x Genomics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where 10x Genomics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether 10x Genomics' disclosed peer group is defensible, who names 10x Genomics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
217 figures on this page: 212 cited to the filing that reported them, 5 calculated from figures it prints.
212 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001628280-26-041651
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-027201
    Chief Executive Officer Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Non-Employee Director Compensation Table · and 2 more sections
  3. 0001770787-25-000040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001770787-25-000018
    Summary Compensation Table
  5. 0001770787-24-000040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001770787-24-000029
    Summary Compensation Table
  7. 0001770787-23-000034
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001770787-22-000032
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “10x Genomics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/TXG (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about 10x Genomics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers 10x Genomics discloses

The companies named in TXG's own disclosed peer group.

Azenta, Inc.Bio-Techne Corp.Certara, Inc.GoodRx Holdings, Inc.Haemonetics CorporationInsulet CorporationiRhythm Technologies, Inc.Maravai Lifesciences Holdings, Inc.NovoCure LimitedPenumbra, Inc.Repligen Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy